3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Melanoma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hemangiosarcoma
1
Interventions
Cyclophosphamide
29
fludarabine phosphate
22
Whole-Body Irradiation
20
Mycophenolic Acid
20
fludarabine
19
asciminib
19
nilotinib
16
Tacrolimus
13
Imatinib Mesylate
13
Melphalan
11
Dasatinib
9
Sirolimus
8
Peripheral Blood Stem Cell Transplantation
8
Thiotepa
7
Granulocyte Colony-Stimulating Factor
7
Busulfan
7
bosutinib
6
Mesna
6
Cyclosporine
6
ponatinib
5
Stem Cell Transplantation
5
Filgrastim
5
venetoclax
4
ruxolitinib
4
blinatumomab
4
Specimen Handling
4
Cyclosporins
4
thymoglobulin
3
Bone Marrow Transplantation
3
Antilymphocyte Serum
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
peginterferon alfa-2a
×
1 year
×
Clear all
NCT02201459
2025-10-02
PETALs
Hospices Civils de Lyon
Phase 3
Completed
200 enrolled